Tagged with oncology

Taiwan James Yang, Director of the Department of Oncology at National Taiwan University Hospital and Director of the Graduate Institute of Oncology at National Taiwan University, discusses the important role of oncology research in developing the Taiwanese pharmaceutical market as well as the new National Taiwanese University Cancer Center (which will…

Taiwan James Chen, founder and Chairman of the board of Vetco, the first Taiwan-based veterinary company to have successfully developed an innovative veterinary oncology product, documents the main specificities of Vetco’s flagship product, Antican®, as well as his strategy to bring this ground-breaking treatment onto the most advanced animal health markets…

Taiwan In an exclusive interview, Amy Huang, general manager of OBI Pharma, shares her plans to bolster the international development of the company and further strengthen its expertise throughout the drug development process. She also elaborates on the key next steps that lie ahead for OBI Pharma’s flagship immuno-oncology therapy, Adagloxad…

Taiwan Founded in 2012, Senhwa Biosciences is mainly engaged in the development and clinical study of small molecule drugs to treat various types of cancer, and its drug development pipelines include CX-5461, a first-in-class drug using G-quadruplex (G4) stabilizer as a mechanism as well as the casein kinase 2 (CK2) inhibitor…

Taiwan Jui-Lin Chen, CEO of MiCareo, provides insights into the development of MiSelect, Micareo’s pioneering platform for the analysis of Circulating Tumor Cells (CTC) and other rare cells, which proudly stands as the best product available to physicians for cancer prognosis as well as the perfect companion diagnostic for drug development…

Taiwan Chen Min-Che, founder and managing director of Asclepiumm, provides insights into the main milestones reached and the new partnership opportunities considered by this exciting biotech company, whose Antibody Switch-on Cytotoxicity (ASC) technology platform could contribute to bringing onto the global market a novel class of “smart cell-penetrating proteins” in multiple…

Italy Professor Angelo Corti, Director of the Experimental Oncology division of the SRSI, discusses approaches to oncology research and the institute´s significant contribution to the field in Italy. What is the philosophy of the SRSI’s oncology division towards oncology research? The development of new strategies to improve cancer prevention, detection and…

Mexico Zurich Pharma was created with the vision of becoming a leader in the oncology segment at the international level. General manager and founder, Orlando Silva Fernandéz, discusses how state-of-the-art technology will help the company move to the next level. Zurich Pharma was founded back in 2004. What has been the…

Switzerland Well-funded and with a stellar pipeline, TESARO is an up and coming Boston-based oncology biotech ready to launch their two first products in the European market in 2017. Orlando, we understand your background in the biotech industry is with Amgen. After a career with the biggest of the biotechs, what…

Taiwan Ten years after its creation in 2005, InnoPharmax was ranked seventh fastest growing technology company in Taiwan in Deloitte’s “Technology Fast 500 Asia Pacific” annual ranking. CS Hsu, founder and president of InnoPharmax, introduces the company’s most fundamental asset – OralPAS®, its unique technology platform, and documents the promising development…

Greece Appointed in the midst of the Greek economic crisis, compounded by significant changes at the corporate Merck brand, Merck Greece’s MD, Konstantinos Kofinas, did not shy away from challenges. He speaks about his leadership approach, Merck’s key therapeutic areas in Greece, as well as industry collaboration in creating a sustainable…

Mexico Abelardo Meneses García, General Director at the National Cancer Institute of Mexico (INCan), explains the evolution of cancer’s footprint in Mexico and showcases how the institute has been investing in enlarging its capabilities to become the national and regional reference for cancer treatment. Could you please introduce to our international…